Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
-
- Nakamura Hideta
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Miyagi Kazuya
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Otsuki Mariko
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Higure Yuuri
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Nishiyama Naoya
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Kinjo Takeshi
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Nakamatsu Masashi
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Haranaga Shusaku
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Tateyama Masao
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
-
- Fujita Jiro
- Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
この論文をさがす
抄録
<p>Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 59 (22), 2945-2949, 2020-11-15
一般社団法人 日本内科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390286426515593216
-
- NII論文ID
- 130007939912
-
- ISSN
- 13497235
- 09182918
-
- HANDLE
- 20.500.12000/47366
-
- PubMed
- 32963155
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可